Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups (This dataset does not contain this module)
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE138267

Dataset summary for GSE138267

Datast information	Dataset	GSE138267
	PMID	33521652
	Raw data ID/link	PRJNA575243
	Organism	Homo sapiens
	Source	CDX
	Tissue	Tumor tissue
	Cancer type level1	Lung cancer
	Cancer type level2	Small cell lung cancer (SCLC)
	Regimen	NA
	Drug type	Chemotherapy
	Sample size	resistant 4, sensitive 4
	Cell number	61001
	Extract protocol	10x genomics
	Data processing	CellRanger 2.0.0
	Public date	Public on Feb 12, 2020
	Description	This dataset has 8 PDX.

Top

Drug summary for GSE138267

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"" is not included in the drug list.

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types

Umap of conditions

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
THRA	ENSG00000126351	0.365756	0.00e+00	0.00e+00	0.327	0.118	Malignant cells	NA
MSN	ENSG00000147065	0.364616	0.00e+00	0.00e+00	0.403	0.166	Malignant cells	NA
GTSE1	ENSG00000075218	0.364394	0.00e+00	0.00e+00	0.319	0.194	Malignant cells	NA
ACAA2	ENSG00000167315	0.363964	0.00e+00	0.00e+00	0.777	0.766	Malignant cells	NA
PTBP1	ENSG00000011304	0.363191	0.00e+00	0.00e+00	0.779	0.799	Malignant cells	NA
DBN1	ENSG00000113758	0.362821	0.00e+00	0.00e+00	0.519	0.307	Malignant cells	NA
HOXB4	ENSG00000182742	0.362608	0.00e+00	0.00e+00	0.452	0.265	Malignant cells	NA
TOP1	ENSG00000198900	0.36201	0.00e+00	0.00e+00	0.582	0.436	Malignant cells	NA
TAF15	ENSG00000276833	0.361335	0.00e+00	0.00e+00	0.516	0.296	Malignant cells	NA
NR0B2	ENSG00000131910	0.361107	0.00e+00	0.00e+00	0.389	0.243	Malignant cells	NA
EIF4E2	ENSG00000135930	0.360716	0.00e+00	0.00e+00	0.534	0.276	Malignant cells	NA
TIFA	ENSG00000145365	0.360485	0.00e+00	0.00e+00	0.415	0.227	Malignant cells	NA
PDIA3	ENSG00000167004	0.360339	0.00e+00	0.00e+00	0.863	0.856	Malignant cells	NA
H2AFY	NA	0.359671	0.00e+00	0.00e+00	0.958	0.958	Malignant cells	NA
ATP5O	NA	0.359221	0.00e+00	0.00e+00	0.959	0.865	Malignant cells	NA
AK3	ENSG00000147853	0.358036	0.00e+00	0.00e+00	0.51	0.316	Malignant cells	NA
CHD2	ENSG00000173575	0.357752	0.00e+00	0.00e+00	0.462	0.239	Malignant cells	NA
ZNF322	ENSG00000181315	0.357074	0.00e+00	0.00e+00	0.339	0.146	Malignant cells	NA
NSRP1	ENSG00000126653	0.356651	0.00e+00	0.00e+00	0.529	0.306	Malignant cells	NA
ITPA	ENSG00000125877	0.356229	0.00e+00	0.00e+00	0.521	0.265	Malignant cells	NA
SPC25	ENSG00000277909	0.355794	0.00e+00	0.00e+00	0.291	0.177	Malignant cells	NA
SCGB2A1	ENSG00000124939	0.355178	0.00e+00	0.00e+00	0.313	0.206	Malignant cells	NA
KLK11	ENSG00000167757	0.354528	0.00e+00	0.00e+00	0.513	0.474	Malignant cells	NA
PRPSAP2	ENSG00000141127	0.354078	0.00e+00	0.00e+00	0.414	0.167	Malignant cells	NA
TMEM145	ENSG00000167619	0.354063	0.00e+00	0.00e+00	0.289	0.071	Malignant cells	NA
HOXD1	ENSG00000128645	0.353736	0.00e+00	0.00e+00	0.323	0.127	Malignant cells	NA
CHMP1A	ENSG00000131165	0.353377	0.00e+00	0.00e+00	0.477	0.228	Malignant cells	NA
HILPDA	ENSG00000135245	0.352957	0.00e+00	0.00e+00	0.481	0.641	Malignant cells	NA
TFAP2A	ENSG00000137203	0.352653	0.00e+00	0.00e+00	0.349	0.129	Malignant cells	NA
EIF1AY	ENSG00000198692	0.352604	0.00e+00	0.00e+00	0.295	0.087	Malignant cells	NA
GGNBP2	ENSG00000275099	0.352237	0.00e+00	0.00e+00	0.721	0.704	Malignant cells	NA
FRG1	ENSG00000275145	0.351948	0.00e+00	0.00e+00	0.507	0.269	Malignant cells	NA
MYEOV2	NA	0.350623	0.00e+00	0.00e+00	0.793	0.679	Malignant cells	NA
BNIP2	ENSG00000140299	0.350581	0.00e+00	0.00e+00	0.395	0.157	Malignant cells	NA
C1orf86	NA	0.349959	0.00e+00	0.00e+00	0.566	0.385	Malignant cells	NA
DEF8	ENSG00000140995	0.349866	0.00e+00	0.00e+00	0.416	0.191	Malignant cells	NA
MYBL2	ENSG00000101057	0.349568	0.00e+00	0.00e+00	0.356	0.192	Malignant cells	NA
PCSK2	ENSG00000125851	0.348709	0.00e+00	0.00e+00	0.543	0.556	Malignant cells	NA
ZWINT	ENSG00000122952	0.348188	3.94e-16	1.10e-11	0.587	0.701	Malignant cells	NA
NDUFS4	ENSG00000164258	0.347702	0.00e+00	0.00e+00	0.754	0.772	Malignant cells	NA
GON4L	ENSG00000116580	0.347496	0.00e+00	0.00e+00	0.394	0.171	Malignant cells	NA
TCEB2	NA	0.347269	0.00e+00	0.00e+00	0.989	0.884	Malignant cells	NA
CHD9	ENSG00000177200	0.347141	0.00e+00	0.00e+00	0.392	0.178	Malignant cells	NA
HERC2	ENSG00000277278	0.346347	0.00e+00	0.00e+00	0.377	0.152	Malignant cells	NA
NOL4	ENSG00000101746	0.345871	0.00e+00	0.00e+00	0.333	0.268	Malignant cells	NA
LMO7	ENSG00000136153	0.345824	0.00e+00	0.00e+00	0.29	0.092	Malignant cells	NA
RRBP1	ENSG00000125844	0.345742	0.00e+00	0.00e+00	0.326	0.124	Malignant cells	NA
BPTF	ENSG00000171634	0.345673	0.00e+00	0.00e+00	0.452	0.245	Malignant cells	NA
ZNF106	ENSG00000103994	0.345666	0.00e+00	0.00e+00	0.34	0.134	Malignant cells	NA
ROCK1	ENSG00000067900	0.345319	0.00e+00	0.00e+00	0.559	0.388	Malignant cells	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	3.30e-15	1.60e-14	1319	781	101	23467	Malignant cells	AKAP1,ANXA2,ATG12,AURKA,CDK4,CDKN1B,TP53,CIAPIN1,DLK1,GSTP1,SLC2A1,HIF1A,HMGA1,HOXB3,ID1,IDH2,IFI27,ISG15,PKM,RPS6,SOX2,SOX4,STMN1,TPD52,TYMS,SLC25A5,TFAP2A,ARID1A,ATG4B,BNIP2,BRD4,BRD7,CCNB1,CDK1,CCNG1,ALCAM,CDC27,CDKN2A,CRBN,CREB1,CXCR4,DCK,DNMT3A,DHFR,EHF,ERCC1,EZR,FIS1,FTL,GAPDH,GAS6,NR3C1,HAX1,HDAC1,HMGB2,HMGN5,HNRNPU,HSPB1,EIF4A3,TCF4,KDM5B,KLF4,LDHA,LRRFIP1,MDM4,MYBL2,NQO1,NUCKS1,TP73,PABPC1,AGPAT2,PTPN1,HRAS,REV1,RRM2,RSF1,SDHB,SMC4,SOCS3,SRSF2,STAT3,SUZ12,TMEM54,TOP1,TUSC3,UBE2C,USP14,USP22,UCP2,WLS,YBX1,ENO1,GNAS,CALR,EIF4EBP1,BRD2,NKX2-1,G3BP1,PMVK,EBP,CERS6
Drug Inactivation by Structure Modification	1.90e-01	4.00e-01	1319	27	3	23467	Malignant cells	GSTP1,DCK,CMPK1
Aberration of the Drug's Therapeutic Target	2.40e-01	4.00e-01	1319	90	7	23467	Malignant cells	CDK4,TP53,IDH2,CDKN2A,CRBN,DHFR,TOP2A
Irregularity in Drug Uptake and Drug Efflux	3.50e-01	4.30e-01	1319	37	3	23467	Malignant cells	SLC3A2,SLC2A1,TAP1
Epigenetic Alteration of DNA, RNA or Protein	9.90e-01	9.90e-01	1319	455	16	23467	Malignant cells	TP53,H2AFY,IDH2,EIF4G2,LMNA,TYMS,PMAIP1,CDKN2A,CXCR4,DNMT3A,GAPDH,SMC4,TIMP1,MALAT1,GDI2,MT-CO2

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__GCM1_SPDEF_RTGNKGGCGGAWG_CAP_repr	3.63	0.0606	GCM1; SPDEF (directAnnotation).	Malignant cells
	transfac_pro__M01219	3.55	0.06	SP1 (directAnnotation). SP3 (inferredBy_Orthology).	Malignant cells
	transfac_pro__M07397	3.53	0.0598	ZNF148 (directAnnotation).	Malignant cells
	metacluster_131.7	3.43	0.059	EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; EGR3; EGR3; EGR3; EGR3; EGR4; EGR4; WT1 (directAnnotation). EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; WT1; ZBTB43; ZBTB43; ZBTB43; ZBTB43; ZBTB5; ZBTB5; ZBTB5; ZBTB5; ZBTB7A; ZBTB7A; ZBTB7A; ZBTB7A; ZNF367; ZNF367; ZNF367; ZNF367; ZNF740; ZNF740; ZNF740; ZNF740 (inferredBy_Orthology).	Malignant cells
	metacluster_131.4	3.39	0.0587	EGR2; EGR2; ZFHX2; ZNF141 (directAnnotation).	Malignant cells
	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	3.37	0.0585	GMEB1 (directAnnotation).	Malignant cells
	taipale_cyt_meth__ZNF281_NCCCCTCCCCCN_eDBD_meth	3.35	0.0584	ZNF281 (directAnnotation).	Malignant cells
	metacluster_15.2	3.33	0.0583	E2F1; E2F1; E2F1; E2F1; E2F1; E2F3; E2F4; E2F4; E2F4; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F7; TFDP1; TFDP2; ZNF566; ZNF566; ZNF574 (directAnnotation). E2F3; E2F3; E2F4 (inferredBy_Orthology).	Malignant cells
	metacluster_7.13	3.32	0.0582	ZFX (directAnnotation).	Malignant cells
	metacluster_3.11	3.32	0.0582	SP1; SP1; SP2; SP3; SP3; SP4 (directAnnotation).	Malignant cells

Page: 1 2 3 4 5

Motifs and TFs regulating down-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	4.28	0.0499	ETS2 (directAnnotation).	Malignant cells
	jaspar__MA1483.2	3.94	0.0476	ELF2 (directAnnotation).	Malignant cells
	transfac_pro__M05481	3.92	0.0474	ZNF202 (directAnnotation).	Malignant cells
	transfac_pro__M05846	3.63	0.0454	ZNF689 (directAnnotation).	Malignant cells
	transfac_pro__M06827	3.58	0.045	ZBTB11 (directAnnotation).	Malignant cells
	taipale_tf_pairs__MYBL1_ELF1_NMCCGGAACCGTTR_CAP_repr	3.57	0.0449	ELF1; MYBL1 (directAnnotation).	Malignant cells
	transfac_pro__M05522	3.52	0.0446	ZNF341 (directAnnotation).	Malignant cells
	swissregulon__hs__ETV6	3.49	0.0444	ETV6 (directAnnotation).	Malignant cells
	transfac_pro__M05298	3.42	0.0439	OVOL3 (directAnnotation).	Malignant cells
	metacluster_33.5	3.35	0.0434	MTF1 (inferredBy_Orthology).	Malignant cells

Page: 1 2 3 4

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
ETS2	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	up	Malignant cells	NA
ELF2	jaspar__MA1483.2	up	Malignant cells	NA
ELF2	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	up	Malignant cells	NA
TFAP2A	tfdimers__MD00275	up	Malignant cells	NA
HES6	jaspar__MA1493.1	up	Malignant cells	NA
CHD2	metacluster_172.6	up	Malignant cells	NA
ZNF281	taipale_cyt_meth__ZNF281_NCCCCTCCCCCN_eDBD_meth	up	Malignant cells	NA
SP3	metacluster_3.11	up	Malignant cells	NA
SP3	metacluster_3.7	up	Malignant cells	NA
NR3C1	metacluster_141.5	up	Malignant cells	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."